Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global, and fast-moving consumer healthcare ... With a portfolio of iconic brands, such as Allegra, Doliprane ...

With a portfolio of brands, such as Allegra ... reportedly raised its bid for Sanofi’s consumer health division by around 200 million euros ($217.12 million). While CD&R has emerged as the ...

Sanofi and CD&R partner to ... to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand portfolio and its highly skilled and ...

Sanofi and CD&R enter exclusive negotiations ... innovation and growth to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand ...

Sanofi SAN-1.01%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare ... a business that is home to brands such as Allegra, Dulcolax ...

Sanofi and CD&R enter exclusive negotiations ... innovation and growth to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand ...